Beyond Sovaldi: PCSK9 Inhibitor Costs Are Also On PBMs’ Radar
Executive Summary
The cost of the new class of drugs for hard-to-treat cholesterol could have an even bigger impact on the health care system than Sovaldi, executives from CVS Caremark and Express Scripts caution.